Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study*

Background Biologics are often required for the treatment of hidradenitis suppurativa (HS). However, data on the drug survival of biologics in daily practice are currently lacking. Objectives To assess the drug survival of antitumour necrosis factor biologics in a daily practice cohort of patients with HS and to identify predictors for drug survival. Methods A retrospective multicentre study was performed in two academic dermatology centres in...